Clinical Trial

Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor

Study acronym: FLORA-ACS
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The FLORA-ACS study aims to evaluate the relationship between dysbiosis and high platelet reactivity during treatment with ticagrelor in patients with a history of acute coronary syndromes and investigate the use of rifaximin to eliminate dysbiosis and thus provide effective antiplatelet treatment.
Trial Details
NCT Number NCT07203846
Lead Sponsor Collegium Medicum w Bydgoszczy
Collaborators: Ministry of Science and Higher Education, Poland
Conditions ACS - Acute Coronary Syndrome, Ticagrelor, Microbiota, Platelet Aggregation, Myocardial Infarction (MI), Blood Platelets, Drug Effects, Platelet Aggregation Inhibitors +5 more
Enrollment 50 participants
Start Date 2026-01-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-10-02